Modulation of peptide-dependent allospecific epitopes on HLA-DR4 molecules by HLA-DM

Human Immunology

Volumn 59, Issue 2, 1998, Pages 77-86

  Drover, Sheila ^a,d   Kovats, Susan ^a,b   Masewicz, Susan ^a   Blum, Janice S ^c   Nepom, Gerald T ^a,b  

^a BENAROYA RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DR3 ANTIGEN; HLA DR4 ANTIGEN;

AMINO ACID SEQUENCE; ANTIGEN ANTIBODY REACTION; ANTIGEN PRESENTATION; ANTIGENIC MODULATION; ANTIGENIC VARIATION; ARTICLE; EPITOPE MAPPING; HLA SYSTEM; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEIN CONFORMATION; RECEPTOR OCCUPANCY; T LYMPHOCYTE ACTIVATION;

ANTIBODIES, MONOCLONAL; CELL LINE, TRANSFORMED; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-D ANTIGENS; HLA-DR4 ANTIGEN; HUMANS; PEPTIDES; T-LYMPHOCYTES;

EID: 0032006652     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0198-8859(97)00263-2     Document Type: Article

References (68)

1. Benham A, Tulp A, Neefjes J. Synthesis and assembly of MHC-peptide complexes. Immunol today. 16:1995;359.
2. Cresswell P. Invariant chain structure and MHC class II function. Cell. 84:1996;505.
3. Busch R, Mellins ED. Developing and shedding inhibitions How the MHC class II molecules reach maturity . Curr Opin Immunol. 8:1996;51.
4. Ghosh P, Amaya M, Mellins E, Wiley DC. The structure of an intermediate in class II MHC maturation CLIP bound to HLA-DR3 . Nature. 378:1995;457.
5. Mellins E, Smith L, Arp B, Cotner T, Celis E, Pious D. Defective processing and presentation of exogenous antigens in mutants with normal HLA class II genes. Nature. 343:1990;71.
6. Sette A, Ceman S, Kubo RT, Sakaguchi K, Appella E, Hunt DF, Davis TA, Michel H, Shabanowitz J, Rudersdorf R, Grey HM, DeMars R. Invariant chain peptides in most HLA-DR molecules of an antigen-processing mutant. Science. 258:1992;1801.
7. Riberdy JM, Newcomb JR, Surman MJ, Barbosa JA, Cresswell P. HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides. Nature. 360:1992;474.
8. Ceman S, Rudersdorf R, Long EO, DeMars R. MHC class II deletion mutant expresses normal levels of transgene encoded class II molecules that have abnormal conformation and impaired antigen presentation ability. J Immunol. 149:1992;754.
9. Morris P, Shaman J, Attaya M, Amaya M, Goodman S, Bergman C, Monaco JJ, Mellins E. An essential role for HLA-DM in antigen presentation by class II major histocompatibility molecules. Nature. 368:1994;551.
10. Fling SP, Arp B, Pious D. HLA-DMA and -DMB genes are both required for MHC class II/peptide complex formation in antigen-presenting cells. Nature. 368:1994;554.
11. Denzin LK, Robbins NF, Carboy-Newcomb C, Cresswell P. Assembly and intracellular transport of HLA-DM and correction of the class II antigen-processing defect in T2 cells. Immunity. 1:1994;595.
12. Kovats S, Nepom GT, Coleman M, Nepom B, Kwok WW, Blum JS. Deficient antigen presenting cell function in multiple genetic complementation groups of type II bare lymphocyte syndrome. J Clin Invest. 96:1995;217.
13. Sloan VS, Cameron P, Porter G, Gammon M, Amaya M, Mellins E, Zaller DM. Mediation by HLA-DM of dissociation of peptides from HLA-DR. Nature. 375:1995;802.
14. Denzin LK, Cresswell P. HLA-DM induces CLIP dissociation from MHC class II alpha beta dimers and facilitates peptide loading. Cell. 82:1995;155.
15. Sherman MA, Weber DA, Jensen PE. DM enhances peptide binding to class II MHC by release of invariant chain-derived peptide. Immunity. 3:1995;197.
16. Weber DA, Evavold BD, Jensen PE. Enhanced dissociation of HLA-DR-bound peptides in the presence of HLA-DM. Science. 274:1996;616.
17. Mellins E, Cameron P, Amaya M, Goodman S, Pious D, Smith L, Arp B. A mutant human histocompatibility leukocyte antigen DR molecule associated with invariant chain peptides. J Exp Med. 179:1994;541.
18. Germain RN, Hendrix LR. MHC class II structure, occupancy and surface expression determined by post-endoplasmic reticulum antigen binding. Nature. 353:1991;134.
19. Cotner T, Mellins E, Johnson AH, Pious D. Mutations affecting antigen processing impair class II-restricted allorecognition. J Immunol. 146:1991;414.
20. Weber DA, Terrell NK, Zhang Y, Strindberg G, Martin J, Rudensky A, Braunstein NS. Requirement for peptide in alloreactive CD4+ T cell recognition of class II MHC molecules. J Immunol. 154:1995;5153.
21. Avva RR, Cresswell P. In vivo and in vitro formation and dissociation of HLA-DR complexes with invariant chain-derived peptides. Immunity. 1:1994;763.
22. Sette A, Southwood S, Miller J, Appella E. Binding of major histocompatibility complex class II to the invariant chain-derived peptide, CLIP, is regulated by allelic polymorphism in class II. J Exp Med. 181:1995;677.
23. Bikoff EK, Germain RN, Robertson EJ. Allelic differences affecting invariant chain dependency of MHC class II subunit assembly. Immunity. 2:1995;301.
24. k class II molecules in human APC containing deleted or mutated HLA DM genes. J Immunol. 153:1994;5382.
25. Diment S, Shinde S. Selective processing of exogenous antigens by antigen-presenting cells with deleted MHC genes. J Immunol. 154:1995;530.
26. Stebbins CC, Loss GE Jr, Elias CG, Chervonsky A, Sant AJ. The requirement for DM in class II-restricted antigen presentation and SDS-stable dimer formation is allele and species dependent. J Exp Med. 181:1995;223.
27. Murphy DB, Lo D, Rath S, Brinster RL, Flavell RA, Slanetz A, Janeway CA Jr. A novel MHC class II epitope expressed in thymic medulla but not cortex. Nature. 338:1989;765.
28. Vidal K, Samarut C, Magaud J-P, Revillard J-P, Kaiserlian D. Unexpected lack of reactivity of allogeneic anti-Ia monoclonal antibodies with MHC class II molecules expressed by mouse intestinal epithelial cells. J Immunol. 151:1993;4642.
29. Marrack P, Kappler J. T cells can distinguish between allogeneic major histocompatibility complex products on different cell types. Nature. 332:1988;840.
30. Lombardi G, Sidhu S, Batchelor JR, Lechler RI. Allorecognition of DR1 by T cells from a DR4/DRw13 responder mimics self-restricted recognition of endogenous peptides. Proc Natl Acad Sci USA. 86:1989;4190.
31. Newton-Nash DK. The molecular basis of allorecognition assessment of the involvement of peptide. Human Immunol. 41:1994;105.
32. Sherman LA, Chattopadhyay S. The molecular basis of allorecognition. Annu Rev Immunol. 11:1993;385.
33. Drover S, Marshall WH, Kwok WW, Nepom GT, Karr RW. Amino acids in the peptide-binding groove influence an antibody-defined, disease-associated HLA-DR epitope. Scand J Immunol. 39:1994;539.
34. Kovats S, Drover S, Marshall W, Freed D, Whiteley P, Nepom GT, Blum JS. Coordinate defects in HLA class II expression and antigen presentation in bare lymphocyte syndrome. J Exp Med. 179:1994;2017.
35. Rammensee HG, Friede T, Stevanoviic S. MHC ligands and peptide motifs first listing . Immunogenet. 41:1995;178.
36. Brown JH, Jardetzky TS, Gorga JC, Stern LJ, Urban RG, Strominger JL, Wiley DC. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature. 364:1993;33.
37. Stern LJ, Brown JH, Jardetzky TS, Gorga JC, Urban RG, Strominger JL, Wiley DC. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature. 368:1994;215.
38. Fu X-T, Bono CP, Woulfe SL, Swearingen C, Summers NL, Sinigaglia F, Sette A, Schwartz BD, Karr RW. Pocket 4 of the HLA-DR(α,β1*0401) molecule is a major determinant of T cell recognition of peptide. J Exp Med. 181:1995;915.
39. Nepom GT, Erlich H. MHC class II molecules and autoimmunity. Ann Rev Immunol. 9:1991;493.
40. Hammer J, Gallazzi F, Bono E, Karr RW, Guenot J, Valsasnini P, Nagy ZA, Sinigaglia F. Peptide binding specificity of HLA-DR4 molecules Correlation with rheumatoid arthritis association . J Exp Med. 181:1995;1847.
41. Kwok WW, Schwarz D, Nepom BS, Thurtle PS, Hock RA, Nepom GT. HLA-DQ molecules form α-β heterodimers of mixed allotype. J Immunol. 141:1988;3123.
42. Ervin P-E, Nilsson K. Beta-2-microglobulin production in vitro by human hemapoietic, mesenchymal, and epithelial cells. J Immunol. 112:1974;137.
43. Hume CR, Shookster LA, Collins N, O'Reilly R, Lee JS. Bare lymphocyte syndrome altered HLA class II expression in B cell lines derived from two patients . Human Immunol. 25:1989;1.
44. Bull M, van Hoef A, Gorski J. Transcription analysis of class II human leukocyte antigen genes from normal and immunodeficient B lymphocytes, using polymerase chain reaction. Mol Cell Biol. 10:1990;3792.
45. Durant B, Kobr M, Reith W, Mach B. Function complementation of major histocompatibility complex class II regulatory mutants by purified X-box-binding protein RFX. Mol Cell Biol. 14:1994;6839.
46. Salter RD, Howell DN, Cresswell P. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenet. 21:1985;235.
47. Mickelson EM, Beatty PG, Storb R, Hansen JA. Immune responses in an untransfused patient with aplastic anemia Analysis of cytotoxic and proliferative T cell clones . Human Immunol. 10:1984;189.
48. Drover S, Karr RW, Kovats S, Nepom GT, Marshall WH. Amino acids in the groove influence an antibody-defined disease associated HLA-DR epitope. Human Immunol. 37:(Suppl 1):1993;67.
49. Drover S, Fu XT, Karr RW, Marshall WH. Analysis of monoclonal antibodies specific for unique and shared determinants on HLA-DR4 molecules. Human Immunol. 40:1994;51.
50. Lampson LA, Levy R. Two populations of Ia-like molecules on a human B cell line. J Immunol. 135:1980;293.
51. Chicz RM, Urban RG, Gorga JC, Vignali DA, Lane WS, Strominger JL. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med. 178:1993;27.
52. Kirschmann DA, Duffin KL, Smith CE, Welply JK, Howard SC, Schwartz BD, Woulfe SL. Naturally processed peptides from rheumatoid arthritis associated and non-associated HLA-DR alleles. J Immunol. 155:1995;5655.
53. Pierre P, Denzin LK, Hammond C, Drake JR, Amigorena S, Cresswell P, Mellman I. HLA-DM is localized to conventional and unconventional MHC class II-containing endocytic compartments. Immunity. 4:1996;229.
54. Sanderson F, Kleijmeer MJ, Kelly A, Verwoerd D, Tulp A, Neefjes JJ, Geuze HJ, Trowsdale J. Accumulation of HLA-DM, a regulator of antigen presentation, in MHC class II compartments. Science. 266:1994;1566.
55. Kropshofer H, Vogt AB, Moldenhauer G, Hammer J, Blum JS, Hämmerling GJ. Editing of the HLA-DR-peptide repertoire by HLA-DM. EMBO J. 15:1996;6144.
56. Fung-Leung W-P, Surh CD, Liljedahl M, Pang J, Leturcq D, Peterson PA, Webb SR, Karlsson L. Antigen presentation and T cell development in H2-M-deficient mice. Science. 271:1996;1278.
57. Katz JF, Stebbins C, Appella E, Sant AJ. Invariant chain and DM edit self-peptide presentation by major histocompatibility complex (MHC) class II molecules. J Exp Med. 184:1996;1747.
58. Monji T, McCormack AL, Yates JR III, Pious D. Invariant-cognate peptide exchange restores class II dimer stability in HLA-DM mutants. J Immunol. 153:1994;4468.
59. b by alloreactive cytotoxic T lymphocytes. Nature. 341:1989;749.
60. Loss GE Jr, Elias CG, Fields PE, Ribaudo RK, McKisic M, Sant AJ. Major histocompatibility complex class II-restricted presentation of an internally synthesized antigen displays cell-type variability and segregates from the exogenous class II and endogenous class I presentation pathways. J Exp Med. 178:1993;73.
61. Demotz S. The ligands of the class II major histocompatibility complex-restricted T cells. Chem Immunol. 57:1993;18.
62. Viner NJ, Nelson CA, Deck B, Unanue ER. Complexes generated by the binding of free peptides to class II molecules are antigenically diverse compared with those generated by intracellular processing. J Immunol. 156:1994;2365.
63. Griffin JP, Chu R, Harding CV. Early endosomes and a late endocytic compartment generate different peptide-class II MHC complexes via distinct processing mechanisms. J Immunol. 158:1997;1523.
64. Lindner R, Unanue ER. Distinct antigen MHC class II complexes generated by separate processing pathways. EMBO J. 15:1997;6910.
65. Khanna R, Burrows SR, Steigerwald-Mullen PM, Moss DJ, Kurilla MG, Cooper L. Targeting Epstein-Barr virus nuclear antigen 1 (EBNA1) through the class II pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes evidence for HLA-DM-independent processing . Int Immunol. 9:1997;1537.
66. Denzin LK, Sant'Angelo DB, Hammond C, Surman MJ, Cresswell P. Negative regulation by HLA-DO of MHC class II-restricted antigen processing. Science. 278:1997;106.
67. Liljedahl M, Kuwana T, Fung-Leung W-P, Jackson MR, Peterson PA, Karlsson L. HLA-DO is a lysosomal resident which requires association with HLA-DM for efficient intracellular transport. EMBO J. 15:1997;4817.
68. Douek DC, Altmann DM. HLA-DO is an intracellular class II molecule with distinctive thymic expression. Int Immunol. 9:1997;355.